Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Harpoon Therapeutics, an immuno-oncology company pioneering a new class of T cell engaging therapeutics, announced today that the first patient... Read More